Working capital intensity remains high
IPO proceeds of ₹20 crore are earmarked for working capital, indicating structurally high inventory and receivable requirements.
medium · analyst_questionAakaar Medical Technologies Ltd — Q4 FY26
Aakaar Medical reported FY26 revenue of ₹66.9 crore (up 8.6% YoY) with EBITDA of ₹10.97 crore and PAT of ₹6.6 crore, both at record levels.
bullish
medium
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
H2 margin sustainability questioned
Analyst asked if 26% EBITDA margin in H2 was sustainable or due to one-off lower conference costs; management acknowledged H2 typically has lower expenses.
medium · analyst_questionDeferred demand normalization risk
H2 revenue growth of 64% HoH may partly reflect deferred demand from H1 credit tightening; FY27 growth could normalize.
medium · analyst_questionDependence on new product launches
Growth hinges on successful ramp-up of new products (Latigo, VM exosomes) which faced regulatory delays; any further delays could impact revenue.
medium · management_commentary